Journal of Nanobiotechnology | |
In vitro assessment of antibody-conjugated gold nanorods for systemic injections | |
Research | |
Raffaella Mercatelli1  Andrea Ravalli1  Giovanna Marrazza1  Enrico Mini2  Giovanni Romano3  Alessio Gnerucci3  Franco Fusi3  Sonia Centi3  Ida Landini4  Stefania Nobili4  Francesca Tatini5  Roberto Pini5  Fulvio Ratto5  | |
[1] Dipartimento di Chimica ‘Ugo Shiff’, Università degli Studi di Firenze, Via della Lastruccia 3, 50019, Sesto Fiorentino, Italy;Dipartimento di Medicina Sperimentale e Clinica, Università degli Studi di Firenze, Largo Brambilla 3, 50134, Firenze, Italy;Dipartimento di Scienze Biomediche Sperimentali e Cliniche ‘Mario Serio’, Università degli Studi di Firenze, Viale Pieraccini 6, 50139, Firenze, Italy;Dipartimento di Scienze della Salute, Università degli Studi di Firenze, Viale Pieraccini 6, 50139, Firenze, Italy;Istituto di Fisica Applicata ‘Nello Carrara’, Consiglio Nazionale delle Ricerche, Via Madonna del Piano 10, 50019, Sesto Fiorentino, Italy; | |
关键词: Gold nanorods; Cancer antigen 125; Active targeting; Competitive assay; Matrix effect; Blood compatibility; | |
DOI : 10.1186/s12951-014-0055-3 | |
received in 2014-09-10, accepted in 2014-11-22, 发布年份 2014 | |
来源: Springer | |
![]() |
【 摘 要 】
BackgroundThe interest for gold nanorods in biomedical optics is driven by their intense absorbance of near infrared light, their biocompatibility and their potential to reach tumors after systemic administration. Examples of applications include the photoacoustic imaging and the photothermal ablation of cancer. In spite of great current efforts, the selective delivery of gold nanorods to tumors through the bloodstream remains a formidable challenge. Their bio-conjugation with targeting units, and in particular with antibodies, is perceived as a hopeful solution, but the complexity of living organisms complicates the identification of possible obstacles along the way to tumors.ResultsHere, we present a new model of gold nanorods conjugated with anti-cancer antigen 125 (CA125) antibodies, which exhibit high specificity for ovarian cancer cells. We implement a battery of tests in vitro, in order to simulate major nuisances and predict the feasibility of these particles for intravenous injections. We show that parameters like the competition of free CA125 in the bloodstream, which could saturate the probe before arriving at the tumors, the matrix effect and the interference with erythrocytes and phagocytes are uncritical.ConclusionsAlthough some deterioration is detectable, anti-CA125-conjugated gold nanorods retain their functional features after interaction with blood tissue and so represent a powerful candidate to hit ovarian cancer cells.
【 授权许可】
Unknown
© Centi et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
【 预 览 】
Files | Size | Format | View |
---|---|---|---|
RO202311107088362ZK.pdf | 1304KB | ![]() |
【 参考文献 】
- [1]
- [2]
- [3]
- [4]
- [5]
- [6]
- [7]
- [8]
- [9]
- [10]
- [11]
- [12]
- [13]
- [14]
- [15]
- [16]
- [17]
- [18]
- [19]
- [20]
- [21]
- [22]
- [23]
- [24]
- [25]
- [26]
- [27]
- [28]
- [29]
- [30]
- [31]
- [32]
- [33]
- [34]
- [35]
- [36]
- [37]
- [38]
- [39]
- [40]
- [41]
- [42]
- [43]
- [44]
- [45]
- [46]
- [47]
- [48]
- [49]
- [50]
- [51]
- [52]
- [53]
- [54]
- [55]
- [56]
- [57]
- [58]
- [59]
- [60]
- [61]
- [62]
- [63]
- [64]
- [65]
- [66]
- [67]
- [68]
- [69]
- [70]
- [71]